Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: The Hong Kong diabetes registry

Diabetes

Volumn 59, Issue 5, 2010, Pages 1254-1260

  Yang, Xilin ^a   Ko, Gary T C ^a   So, Wing Yee ^a   Ma, Ronald C W ^a   Yu, Linda W L ^a   Kong, Alice P S ^a   Zhao, Hailu ^a   Chow, Chun Chung ^a   Tong, Peter C Y ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN DERIVATIVE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CELL GROWTH; CELL PROLIFERATION; CHINESE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HONG KONG; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; SMOKING;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS;

EID: 77951835127     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1371     Document Type: Article

References (33)

1. Straus DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev 1984;5:356-369
2. Kim YI. Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? Nutr Rev 1998;56:275-279
3. LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 2008;116(Suppl 1.):S4-S6
4. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60
5. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52: 1732-1744
6. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-1754
7. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765
8. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
9. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-1708.
10. Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009;52: 1971-1973
11. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer: an unsubstantiated allegation. Diabetes Technol Ther 2009;11:473-476
12. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:412-418 (Pubitemid 36578478)
13. Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-567 (Pubitemid 46354334)
14. Best JD, O'Neal DN. Diabetic dyslipidaemia: current treatment recommendations. Drugs 2000;59:1101-1111 (Pubitemid 30339136)
15. Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, Tong PC, Chan JC. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008;179:427-437
16. Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q, Cockram CS, Chow CC, Chan JC, Tong PC. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 2008;15:597-607 (Pubitemid 351880846)
17. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006;184:295-301 (Pubitemid 43049713)
18. Chen J, Mehta JL. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep 2006;8:139-143 (Pubitemid 43796691)
19. Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, Kong AP, Ozaki R, Yeung CY, Xu G, Tong PC, Chan JC. Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 2009;58:1518-1525
20. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, Bonaduce D, Condorelli M, Reaven PD, Napoli C. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001;22:2075-2084 (Pubitemid 33091450)
21. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M. Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative: The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med 1993;10:371-377
22. Yang X, So WY, Tong PC, Ma RC, Kong AP, Lam CW, Ho CS, Cockram CS, Ko GT, Chow CC, Wong VC, Chan JC. Development and validation of an all-cause mortality risk score in type 2 diabetes-The Hong Kong Diabetes Registry. Arch Intern Med 2008;168:451-457 (Pubitemid 351547208)
23. So WY, Yang X, Ma RC, Kong AP, Lam CW, Ho CS, Cockram CS, Ko GT, Chow CC, Wong V, Tong PC, Chan JC. Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2008;24:238-246 (Pubitemid 351385542)
24. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920 (Pubitemid 37323253)
25. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-2944 (Pubitemid 44484685)
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
27. Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H, Luk AO, Lam CW, Ho CS, Tong PC, Chan JC. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009;32:1826-1832
28. Harrell F. Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Spinger-Varlag, 2001
29. Yang X, Ko GT, So WY, Ma RC, Kong AP, Lam CW, Ho CS, Chow CC, Tong PC, Chan JC, Hong Kong Diabetes Registry. Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Care 2008;31:2294-2300
30. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625
31. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305 (Pubitemid 40813563)
32. Feinstein AR. Clinical biostatistics: XI, sources of 'chronology bias' in cohort statistics. Clin Pharmacol Ther 1971;12:864-879
33. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Stat Med 2002;21:3317-3324 (Pubitemid 35314652)